OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland. Show more

115 Pullman Crossing Road, Grasonville, MD, 21638, United States

Biotechnology

Healthcare

Market Cap

53.77M

52 Wk Range

$1.12 - $2.57

Previous Close

$1.36

Open

$1.36

Volume

188,725

Day Range

$1.32 - $1.38

Enterprise Value

70.37M

Cash

269.8K

Avg Qtr Burn

-3.73M

Insider Ownership

24.94%

Institutional Own.

4.52%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OST-HER2 Details Pediatric lung metastatic osteosarcoma	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OST-504 Details 2L prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.